NASDAQ · AGEN
Healthcare · Biotechnology
$8.73
Up+$0.37 (+4.43%)
Updated Oct 6, 2026, 7:39 AM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AGEN
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
AGEN closed at $8.73 after 20 trading sessions, up 17.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $8.54 | $8.76 | $8.1101 | $8.73 | 956.3K |
| Oct 2, 2026 | $8.36 | $8.6126 | $8.08 | $8.36 | 1.09M |
| Oct 1, 2026 | $9.95 | $9.99 | $8.28 | $8.33 | 1.95M |
| Sep 30, 2026 | $9.92 | $10.31 | $9.62 | $9.93 | 1.37M |
| Sep 29, 2026 | $9.66 | $10.06 | $9.43 | $9.89 | 1.5M |
| Sep 28, 2026 | $8.71 | $9.71 | $8.47 | $9.43 | 2.77M |
| Sep 25, 2026 | $8.57 | $8.68 | $8.40 | $8.54 | 672.4K |
| Sep 24, 2026 | $8.32 | $8.60 | $8.20 | $8.50 | 636.61K |
| Sep 23, 2026 | $8.70 | $8.70 | $8.39 | $8.40 | 610.17K |
| Sep 22, 2026 | $8.26 | $8.82 | $8.16 | $8.70 | 994.14K |
| Sep 21, 2026 | $7.80 | $8.60 | $7.60 | $8.33 | 1.3M |
| Sep 18, 2026 | $7.48 | $7.88 | $7.33 | $7.85 | 2.08M |
| Sep 17, 2026 | $7.31 | $7.40 | $7.085 | $7.22 | 765.42K |
| Sep 16, 2026 | $7.25 | $7.33 | $7.055 | $7.21 | 687.08K |
| Sep 15, 2026 | $7.05 | $7.19 | $6.81 | $7.16 | 779.52K |
| Sep 14, 2026 | $7.03 | $7.18 | $6.82 | $7.13 | 752.31K |
| Sep 11, 2026 | $6.93 | $7.02 | $6.70 | $6.94 | 790.46K |
| Sep 10, 2026 | $6.76 | $7.04 | $6.66 | $6.89 | 893.56K |
| Sep 9, 2026 | $7.595 | $7.605 | $6.782 | $6.86 | 1.45M |
| Sep 8, 2026 | $8.14 | $8.18 | $7.42 | $7.43 | 1.21M |
The latest Smart Investors Daily articles mentioning AGEN.
Company
Market Activity
Research & News
AGEN research
Company profile and research snapshot.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | Chardan Capital | Buy | — |
| Sep 28, 2026 | Rodman & Renshaw | Buy | — |
| Sep 18, 2026 | Chardan Capital | Buy | — |
| Aug 11, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 30, 2026 | B. Riley Securities | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 29, 2026
Agenus Inc. has surged >195% YTD, driven by optimism around its BOT/BAL combo therapy for MSS colon cancer. Read more on AGEN stock here.
SeekingAlpha · Sep 29, 2026
Agenus (AGEN) bets on BOT/BAL immunotherapy ahead of the ROBBIN Phase 3 MSS colon cancer trial.
Benzinga · Sep 28, 2026
Rodman & Renshaw analyst Michael King initiates coverage on Agenus (NASDAQ:AGEN) with a Buy rating and announces Price Target of $19.
Yahoo · Sep 20, 2026
Agenus now carries an updated implied fair value of about US$26.33 per share, up from US$19.50, which reflects a change of roughly 35% in the price target used in this analysis. Recent Street commentary links these higher targets to the botensilimab plus balstilimab program in microsatellite stable colorectal cancer and to fresh capital that affects how investors think about financing risk. Read on to see how this evolving narrative around Agenus could matter for your own view of the...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AGEN.
